Transcript: Palatin Techs Q3 2026 Earnings Conference Call

Benzinga APIs supply real-time entree to net telephone transcripts and fiscal data. Visit https://www.benzinga.com/apis/ to larn more.

Access the afloat telephone astatine https://www.webcaster5.com/Webcast/Page/2953/54002

Summary

Palatin Techs reported $3.9 cardinal successful collaboration and licence gross for Q3 2026, marking an summation from nary gross successful the anterior year, chiefly owed to the Altanisbac agreement.

The institution recorded a nett nonaccomplishment of $1.4 million, importantly improved from a $4.8 cardinal nett nonaccomplishment successful the erstwhile year, driven by accrued revenue.

Palatin Techs is advancing its melanocortin 4 receptor therapies for uncommon obesity disorders, focusing connected improving tolerability and usability, with plans to taxable an IND for their peptide programme successful Q4 2026.

The institution has strategical partnerships, including with Bergel Ingelheim and Altanisbac Labs, providing non-dilutive superior and aboriginal royalty opportunities.

Management is assured successful processing best-in-class therapies, highlighting improvements successful selectivity and potency, particularly successful their oral tiny molecule program.

Full Transcript

OPERATOR

Hello everyone. Welcome to Palatin's 3rd 4th fiscal twelvemonth 2026 operating results league call. At this time, each participants are connected a perceive lone mode. A question and reply league volition travel the ceremonial presentation. If anyone should necessitate relation assistance during the conference, delight property 0 connected your telephone keypad. As a reminder, this league telephone is being recorded. Before we statesman our remarks, I would similar to punctual you that the statements made by Palatin are not humanities facts and whitethorn beryllium guardant looking statements. These statements are based connected assumptions that whitethorn oregon whitethorn not beryllium to beryllium close and that the existent results whitethorn disagree materially from those anticipated and owed to the assortment of risks and uncertainties discussed successful the Company's caller filings with the Securities and Exchange Commission. Please see specified risks and uncertainties cautiously successful evaluating these guardant looking statements by Palatin's prospects. Now I would similar to crook the telephone implicit to your host, Dr. Carl Spana, President and Chief Executive Officer of Palatin. Please spell ahead. Thank you.

Dr. Carl Spana (President and Chief Executive Officer)

Good greeting and invited to the Palatin 3rd 4th fiscal twelvemonth 2026 call. I'm Dr. Carl Spana, CEO and President of Palatin. With maine connected the telephone contiguous is Steve Wills, Palatin's Chief Financial Officer and Chief Operating Officer. Earlier contiguous we issued a property merchandise reporting Palatin's fiscal results for the 3rd 4th of fiscal twelvemonth 2026 and are present providing a firm update. Today we volition item our Progress advancing our melanocortin 4 receptor based obesity pipeline reappraisal caller strategical and fiscal milestones and outline our priorities arsenic we determination done 2026 followed by a question and reply session. First, I volition crook the telephone implicit to Steve for the fiscal and operating results.